Synopsis
Recognise metastatic malignancy without an identified origin, stabilise urgent complications, perform a focused high-yield diagnostic work-up, and avoid burdensome testing that cannot change treatment or goals.
- Malignancy of undefined primary describes metastatic cancer before a full initial assessment; confirmed cancer of unknown primary remains after appropriate investigation fails to identify origin.
- First confirm malignancy and lineage with adequate tissue; poorly planned broad imaging or tumour markers cannot substitute for pathology.
- History, full examination, basic blood tests and contrast CT chest, abdomen and pelvis form the initial diagnostic core under NICE guidance.
- Immunohistochemistry is used stepwise to establish broad lineage and support plausible origin, conserving tissue for treatment-relevant tests.
- Routine indiscriminate tumour-marker panels, endoscopies and repeated imaging have low specificity and create false leads; add tests only when clinical or pathological evidence points to a site.
- Recognise favourable subsets with site-specific treatment potential, including selected nodal, peritoneal, bone or germ-cell patterns.
- Discuss prognosis and treatment intent early; some patients benefit from systemic therapy, local control or trials while others are best served by symptom-focused care.
- A named CUP multidisciplinary team should coordinate results, prevent duplicated tests and integrate palliative care from diagnosis.
Key red flags
Neurological deficit, obstruction, severe pain, pathological fracture or metabolic deterioration requires emergency treatment before the primary is found.
Investigation priorities
Confirm malignancy, lineage and a plausible organ profile while preserving tissue.
Management branches
The patient has neurological, obstructive, metabolic, haemorrhagic or infective compromise.
- Use ABCDE assessment and activate acute oncology plus the organ-specific emergency team before completing primary-site investigation.
- Obtain the targeted urgent imaging and begin indicated rescue, analgesia and thrombosis or infection management without awaiting every pathology addendum.
- Choose any urgent biopsy or intervention collaboratively so it can also support later diagnosis without compromising immediate safety.
Metastatic malignancy is suspected and the patient is stable enough for investigation.
- Take a complete exposure, family and symptom history; examine skin, nodes, breast, rectal, pelvic, testicular and other sites as clinically appropriate.
- Perform baseline blood tests, contrast CT chest-abdomen-pelvis and an adequate core biopsy with staged immunohistochemistry.
- Present findings at the CUP MDT to classify malignancy, identify favourable subsets and decide which focused additional test could alter treatment.